Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 601–700 of 1,014
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
Richard, E., den Brok, M. G. H. E., & van Gool, W. A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12379 · Cited by 50
Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Evin, G. M. (2016) · BioDrugs · doi:10.1007/s40259-016-0168-3 · Cited by 56
“Two Phase 3 trials in patients with mild to moderate AD, one study with over one thousand asymptomatic APOE ε 4 carriers and the other with one thousand non APOEε 4 carriers, showed no clinical improvement in either group, in spite of changes in CSF biomarkers in the cohort of APOEε 4 carriers [62].”
BackgroundMeasures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Vis, G., Stomrud, E., Nilsson, M., & Hansson, O. (2022) · Brain · doi:10.1093/brain/awac343 · Cited by 57
“4–7 However, the results from such trials have been puzzling.”
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Alzheimer’s Disease, Anesthesia, and Surgery: A Clinically Focused Review
Berger, M., Burke, J. R., Eckenhoff, R. G., & Mathew, J. P. (2014) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2014.04.014 · Cited by 53
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
Voyle, N., Baker, D., Burnham, S. C., Covin, A., Zhang, Z., Sangurdekar, D. P., Tan Hehir, C. A., Bazenet, C., Lovestone, S., Kiddle, S., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150020 · Cited by 50
“For example, in a trial of Bapineuzumab, a humanized anti-A monoclonal antibody, approximately 14% of subjects had low A burden [9].”
BackgroundPharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Wagner, S. L., Rynearson, K. D., Duddy, S. K., Zhang, C., Nguyen, P. D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J. B., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240861 · Cited by 49
“In contrast, immunotherapy approaches that aim at clearing deposited Ab peptides have recently shown potential against AD; however, this is only after years of failures (Gilman et al., 2005; Miles et al., 2013; Salloway et al., 2014).”
Qi, L., Liu, S., Liu, Y.-C., Li, P., & Xu, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115559 · Cited by 54
Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target
Villarejo, L. G., Bachmann, L., Marks, D., Brachthäuser, M., Geidies, A., & Müller, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094656 · Cited by 53
Choroid Plexus Volume, Amyloid Burden, and Cognition in the Alzheimer’s Disease Continuum
Jeong, S. H., Park, C. J., Cha, J., Kim, S.-Y., Lee, S., Kim, Y. J., Sohn, Y. H., Chung, S. J., & Lee, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0118 · Cited by 87
The potential applications of Apolipoprotein E in personalized medicine
Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00154 · Cited by 48
Degenhardt, E. K., Witte, M. M., Case, M. G., Yu, P., Henley, D. B., Hochstetler, H. M., D’Souza, D. N., & Trzepacz, P. T. (2016) · Psychosomatics · doi:10.1016/j.psym.2015.12.002 · Cited by 48
“Salloway et al.36 reported that a greater number of APOE4 noncarriers were PiB-PET negative (36.1”
BackgroundInfluentialNeuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 60
Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?
Dani, M., Brooks, D. J., & Edison, P. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.003 · Cited by 55
Nave, S., Doody, R. S., Boada, M., Grimmer, T., Savola, J.-M., Delmar, P., Pauly-Evers, M., Nikolcheva, T., Czech, C., Borroni, E., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161309 · Cited by 48
Deming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
Staffaroni, A. M., Bajorek, L., Casaletto, K. B., Cobigo, Y., Goh, S. M., Wolf, A., Heuer, H. W., Elahi, F. M., Ljubenkov, P. A., Dever, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.012 · Cited by 47
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
NPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Lathuilière, A., Mach, N., & Schneider, B. L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510578 · Cited by 53
“Mild to moderate AD patients intravenously treated for 18-months with bapineuzumab, an antibody binding specifically to the N-terminus of Aβ, did not show any effect on cognitive function or functional outcome measurements [73].”
BackgroundLiu, Y.-H., Bu, X.-L., Liang, C.-R., Wang, Y.-R., Zhang, T., Jiao, S.-S., Zeng, F., Yao, X.-Q., Zhou, H.-D., Deng, J., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0379-4 · Cited by 47
“This notion was supported by the fact that solanezumab, an antibody against the middle domain of Aβ, is not as effective in reducing the brain Aβ burden [18] compared to bapineuzumab, an antibody against the N-terminus of Aβ that is able to remove brain Aβ deposits, as evidenced by recent immunotherapeutic clinical tr…”
BackgroundResultAmanatkar, H. R., Papagiannopoulos, B., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194203 · Cited by 50
Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
Wischik, C. M., Schelter, B. O., Wischik, D., Storey, J. M. D., & Harrington, C. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170727 · Cited by 54
“In patients taking the same doses of LMTM as add-on to approved anti-dementia treatments, the decline was indistinguishable from controls as randomized or from placebo controls in recently reported studies [54, 55].”
ResultFrequency-dependent exacerbation of Alzheimer’s disease neuropathophysiology
Kastanenka, K. V., Calvo-Rodríguez, M., Hou, S. S., Zhou, H., Takeda, S., Arbel‐Ornath, M., Lariviere, A., Lee, Y. F., Kim, A., Hawkes, J. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44964-z · Cited by 49
Reviving an R&D pipeline: a step change in the Phase II success rate
Wu, S. S., Fernando, K., Allerton, C. M. N., Jansen, K. U., Vincent, M. S., & Dolsten, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.019 · Cited by 48
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 51
Differential expression of MicroRNAs in Alzheimer’s disease: a systematic review and meta-analysis
Yoon, S., Kim, S. E., Ko, Y., Jeong, G. H., Lee, K. H., Lee, J., Solmi, M., Jacob, L., Smith, L., Stickley, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01476-z · Cited by 44
“However, multicenter clinical trials targeting Aβ have not been successful [5], and the outcome of anti-tau therapy is still unclear [6].”
BackgroundWhat lessons can be learned from failed Alzheimer’s disease trials?
Toyn, J. H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034690 · Cited by 53
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
Sugino, H., Watanabe, A., Amada, N., Yamamoto, M., Ohgi, Y., Kostic, D., & Sanchez, R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.006 · Cited by 48
Lathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P. (2016) · Brain · doi:10.1093/brain/aww036 · Cited by 46
“prevention) to better potentiate therapeutic effects (Doody et al., 2014; Salloway et al., 2014).”
ResultENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE
Vellas, B., Bateman, R., Blennow, K., Frisoni, G., Johnson, K., Katz, R., Langbaum, J., Marson, D., Sperling, R., Wessels, A., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.55 · Cited by 44
“In addition, the phase 2 bapineuzumab trial and both the phase 3 trials all showed a modest lowering of CSF p-tau by approximately 10% with treatment, suggestive of downstream effects on the neurodegenerative process that was not associated with any cognitive improvement (48, 49).”
BackgroundSelf-citationPersonality and Incident Alzheimer’s Disease: Theory, Evidence, and Future Directions
Segerstrom, S. C. (2018) · The Journals of Gerontology Series B · doi:10.1093/geronb/gby063 · Cited by 54
“Focus on plaques as causal has been called into question considering large, Phase III pharmacological clinical trials in which clinical progression of mild-to-moderate AD was not affected even when the drug reduced Aβ and tau relative to controls (Doody et al., 2014; Salloway et al., 2014).”
BackgroundUsing sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Self-citationAyton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Nakano, M., Kubota, K., Hashizume, S., Kobayashi, E., Chikenji, T., Saito, Y., & Fujimiya, M. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100149 · Cited by 53
Copper and cuproptosis: new therapeutic approaches for Alzheimer’s disease
Li, X., Chen, X., & Gao, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1300405 · Cited by 48
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
“Previous investigations exploring the efficacy of drugs targeting Aβ have indicated that reductions in amyloid plaques do not lead to alleviation of AD symptoms [107–111].”
Boncoraglio, G. B., Piazza, F., Savoiardo, M., Farina, L., DiFrancesco, J. C., Prioni, S., Tagliavini, F., Parati, E. A., & Giaccone, G. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142376 · Cited by 46
Back to the future: Alzheimer's disease heterogeneity revisited
Au, R., Piers, R. J., & Lancashire, L. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.05.006 · Cited by 45
An effective treatment for Alzheimer's disease must consider both amyloid and tau
Lansdall, C. J. (2014) · Bioscience Horizons · doi:10.1093/biohorizons/hzu002 · Cited by 46
“Due to these safety findings, the highest dose was discontinued (ClinicalTrials.gov Identifier: NCT00575055 and NCT00574132; Salloway et al., 2014) Solanezumab III Failed to reach its cognitive or functional endpoints in either of two double-blind, placebocontrolled trials in patients with mild to…”
BackgroundInfluentialMultidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M., Vellas, B., & Andrieu, S. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.008 · Cited by 45
“The negative results of bapineuzumab [2] and solanezumab [3] phase III trials were an important methodological turning point in AD therapeutic trials.”
BackgroundChen, L., Wei, Z., Chan, K. W. Y., Li, Y., Suchal, K., Bi, S., Huang, J., Xu, X., Wong, P. C., Lu, H., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20941264 · Cited by 47
Sabbagh, M. N., & Cummings, J. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12235 · Cited by 48
Self-citationAlzheimer’s Disease: Drug Discovery
(2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 44
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 50
Irwin, R. W., Solinsky, C. M., Loya, C. M., Salituro, F. G., Rodgers, K. E., Bauer, G., Rogawski, M. A., & Brinton, R. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128313 · Cited by 50
“Recent failed Phase 3 trials targeting beta-amyloid plaques are indicative of the complexity of the multifactorial disease process and highlight the need for alternative innovative therapeutics [3, 4].”
BackgroundImplications of the Approval of Lecanemab for Alzheimer Disease Patient Care
Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 51
“That agent ultimately failed to show benefits.(16) Since then, and up to 2021, there had never been a successful trial of one of these antibodies (see several reviews of these earlier agents for more details.”
BackgroundGiuliani, D., Neri, L., Canalini, F., Calevro, A., Ottani, A., Vandini, E., Sena, P., Zaffe, D., & Guarini, S. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.05.004 · Cited by 42
“However, disappointing results are arising from these novel studies (Salloway et al., 2014), and, therefore, effective approaches to slow down AD progression are still unavailable in clinical practice.”
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
Fuller, J. P., Stavenhagen, J. B., Christensen, S., Kartberg, F., Glennie, M. J., & Teeling, J. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1484-2 · Cited by 44
“Bapineuzumab and Solanezumab both failed in phase III, and a phase III trial for Gantenerumab was abandoned after a futility analysis [12, 23].”
BackgroundAudrain, M., Fol, R., Dutar, P., Potier, B., Billard, J.-M., Flament, J., Alves, S., Burlot, M.-A., Dufayet-Chaffaud, G., Bemelmans, A.-P., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0070-y · Cited by 43
“seem to fit well [22, 23].”
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C., Carrillo, M. C., Bain, L. J., DeMattos, R., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
“Some possible reasons for lack of success include limited dosing due to side effects [4] with limited engagement of the target, unexpected adverse effects with target engagement (g-secretase inhibitors), inclusion of participants without amyloid pathology in phase 3 studies, and potentially treating too late in diseas…”
BackgroundSelf-citationFocused ultrasound as a novel strategy for Alzheimer disease therapeutics
Meng, Y., Volpini, M., Black, S. E., Lozano, A. M., Hynynen, K., & Lipsman, N. (2017) · Annals of Neurology · doi:10.1002/ana.24933 · Cited by 45
Modulation of innate immunity of patients with Alzheimer's disease by omega‐3 fatty acids
Fiala, M., Kooij, G., Wagner, K., Hammock, B., & Pellegrini, M. (2017) · The FASEB Journal · doi:10.1096/fj.201700065r · Cited by 44
Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 48
Effect of active A β immunotherapy on neurons in human Alzheimer's disease
Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4491 · Cited by 44
“The pathological changes induced by Aβ immunotherapy in Aβ and the neuronal features studied here do not seem to be sufficient to alter the clinical course of the disease, as reported in the AN1792 clinical trial [16] and after passive immunization (solanezumab [25], bapineuzumab [24]) – these studies involved patient…”
ResultSuelves, N., Saleki, S., Ibrahim, T., Palomares, D., Moonen, S., Koper, M. J., Vrancx, C., Vadukul, D. M., Papadopoulos, N., Viceconte, N., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01578-x · Cited by 43
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement…”
ResultMonoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
“Even though the biomarker results from the carrier study were positive at some levels, both trials failed to identify the benefit of bapineuzumab regarding clinical outcomes [108,109].”
BackgroundMethodResultInfluentialTondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“It showed a good safety profile, but without clinical effectiveness [116].”
BackgroundAlzheimer's disease and other dementias: advances in 2014
Bateman, R. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70301-1 · Cited by 43
Gault, L. M., Lenz, R. A., Ritchie, C. W., Meier, A., Othman, A. A., Tang, Q., Berry, S., Pritchett, Y., & Robieson, W. Z. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0210-1 · Cited by 43
“Based on neuropathological analysis of patients meeting diagnostic criteria for AD [30, 31] and on recent clinical trial results showing that approximately 30 % of subjects selected with these criteria have negative positron emission tomography scans for amyloid [32, 33], we expect that some subjects in this trial wou…”
BackgroundVaccination strategies in tauopathies and synucleinopathies
Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 45
“Bapineuzumab is a humanized monoclonal antibody that recognizes Ab at the N-terminus (Salloway et al. 2009, 2014).”
BackgroundInfluentialGriffith, C. M., Macklin, L. N., Cai, Y., Sharp, A. A., Yan, X.-X., Reagan, L. P., Strader, A. D., Rose, G. M., & Patrylo, P. R. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180707 · Cited by 43
Fujimoto, K., Matsuoka, E., Asada, N., Tadano, G., Yamamoto, T., Nakahara, K., Fuchino, K., Ito, H., Kanegawa, N., Moechars, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00309 · Cited by 47
Roda, A. R., Esquerda-Canals, G., Martí, J., & Villegas, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100944 · Cited by 56
“Positive effects of Aβ immunotherapy in mice models have been reported [31–33,35], but, unfortunately, human clinical trials have not yet been successful in passing phase 3 [30].”
BackgroundFeasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy
Song, M., Scheifele, M., Barthel, H., van Eimeren, T., Beyer, L., MAREK, K. L., Eckenweber, F., Palleis, C., Kaiser, L., Finze, A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05391-3 · Cited by 50
“This was impressively shown for β-amyloid PET which revealed post hoc that β-amyloid-modifying trials were initiated with more than one third of β-amyloid-negative patients that could likely not pro t from the therapy [25].”
BackgroundEU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS
Aisen, P., Touchon, J., Amariglio, R., Andrieu, S., Bateman, R., Breitner, J., Donohue, M., Dunn, B., Doody, R., Fox, N., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.13 · Cited by 42
“This can be mitigated by combining imaging and other biomarkers (38).”
BackgroundSelf-citationBACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 53
Padilla-Godínez, F. J., Vázquez-García, E. R., Trujillo-Villagrán, M. I., Soto-Rojas, L. O., Palomero‐Rivero, M., Hernández-González, O., Pérez-Eugenio, F., Collazo-Navarrete, O., Arias-Carrión, Ó., & Guerra‐Crespo, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1570553 · Cited by 47
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 49
Qu, A., Huang, F., Li, A., Yang, H., Zhou, H., Long, J., & Shi, L. (2017) · Chemical Communications · doi:10.1039/c6cc07803f · Cited by 44
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 48
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 44
Self-citationClark, I. A., & Vissel, B. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14471 · Cited by 45
“This is in part why removing soluble Aβ or its plaque, until recently the goal of many large clinical trials (Salloway et al., 2014), cannot, of itself, be expected to retard sporadic human AD disease progression.”
BackgroundGustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
“While also showing potential beneficial effects in phase II clinical trials, bapineuzumab later failed in phase III due to nonsignificant changes on primary outcomes and incidence of unfavorable side effects (18-20).”
Hu, X., Teunissen, C. E., Spottke, A. E., Heneka, M. T., Düzel, E., Peters, O., Li, S., Priller, J., Büerger, K., Teipel, S. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.002 · Cited by 49
“Alzheimer’s disease (AD) is a worldwide challenge due to the rapidly increasing number of patients, the associated financial and social burden, and the still lacking treatment to slow disease progression [1,2].”
BackgroundTimmers, M., Tesseur, I., Bogert, J., Zetterberg, H., Blennow, K., Börjesson-Hanson, A., Baquero, M., Boada, M., Randolph, C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 42
Self-citationAnti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Chantran, Y., Capron, J., Alamowitch, S., & Aucouturier, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01534 · Cited by 42
“ARIA-E was found in 17% (36/210) Bapineuzumab-treated subjects, appearing after the first or second infusion, in a dose-dependent manner, with an increased risk in ApoE ε4 carriers (7% among non-carriers, 18% among heterozygous, 36% among homozygous) (71).”
BackgroundImaging of Tau Pathology in Neurodegenerative Diseases: An Update
Beyer, L., & Brendel, M. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.004 · Cited by 46
“Ultimately, such efforts could lead to the successful development of isoform specific tau-PET tracers. showing amyloid-positivity when A β -PET was analyzed after completion of the studies 135 .”
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 44
Jeong, S. Y., Suh, C. H., Shim, W. H., Lim, J., Lee, J., & Kim, S. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201019 · Cited by 60
“001; Figures 2 and 3) compared with other agents.(15-34)”
BackgroundMethodResultInfluentialAlzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development
Grobler, C., van Tongeren, M., Gettemans, J., Kell, D. B., & Pretorius, E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220720 · Cited by 51
“Furthermore, clinical trials found that reduction of A (cid:2) did not improve clinical outcomes [24].”
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
“It has been concluded that this unexpected finding provides a possible cellular explanation for the lack of cognitive improvement by immunotherapy in human studies [135, 136].”
BackgroundPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Sharma, H., & Chandra, P. (2023) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.14.1.15 · Cited by 50
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Loomis, S. J., Miller, R., Castrillo‐Viguera, C., Umans, K., Cheng, W., O'Gorman, J. T., Hughes, R. A., Haeberlein, S. B., & Whelan, C. D. (2023) · Neurology · doi:10.1212/wnl.0000000000207919 · Cited by 45
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Yi, L., Tan, E. K., & Zhou, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05248-x · Cited by 49
“These unsuccessful anti-Aβ antibodies include bapineu-zumab [12], a humanized mAb that targets the N-terminal of Aβ to clear away both fibrillar and soluble Aβ peptides; crenezumab [13], a humanized mAb that binds to monomeric and oligomeric Aβ peptide, as well as gan-tenerumab [14], a fully human…”
BackgroundWhite matter changes from mild cognitive impairment to Alzheimer’s disease: a meta-analysis
Qin, L., Guo, Z., McClure, M. A., & Mu, Q. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01322-5 · Cited by 46
“For instance, Bapineuzumab and Solanezumab, produced by Pfizer, Johnson & Johnson, and Eli Lilly, respectively, did not improve cognitive function in AD patients [4, 5].”
BackgroundPotential Role of Venular Amyloid in Alzheimer’s Disease Pathogenesis
Morrone, C. D., Bishay, J., & McLaurin, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061985 · Cited by 47
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
“…et al. , 2018 a ; Jadhav et al. , 2019), especially in view of the disappointing outcomes from A b -targeting pharmacological and immunological approaches (Sigurdsson, 2008; Giacobini and Gold, 2013; Doody et al. , 2014; Salloway et al. , 2014; Schroeder et al. , 2016; Agadjanyan et al. , 2017).”
Luo, A., Ning, P., Lu, H., Huang, H., Shen, Q., Zhang, D., Xu, F., Yang, L. J., & Xu, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220180 · Cited by 45
Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.007 · Cited by 40
“6% increase in atrophy [8] compared with a 4.”
BackgroundOlfactory deficit: a potential functional marker across the Alzheimer’s disease continuum
Liu, D., Lu, J., Wei, L., Yao, M., Yang, H., Lv, P., Wang, H., Zhu, Y., Zhu, Z., Zhang, X., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1309482 · Cited by 56
“Recent years have witnessed significant advancements in understanding the intricate pathogenesis of AD (Scheltens et al., 2021; Murdock and Tsai, 2023), diagnosis, staging (DeTure and Dickson, 2019), and the development of therapeutic drugs (Doody et al., 2014; Salloway et al., 2014).”
BackgroundSarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
“Before these FDA approvals, research on potential disease-modifying curative treatments remained disap-pointing due to the difficulty of translating promising results from animal models to humans 1–7 .”
Risse, E., Nicoll, A. J., Taylor, W. A., Wright, D., Badoni, M., Yang, X., Farrow, M. A., & Collinge, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.637124 · Cited by 46
Ivanoiu, A., Pariente, J., Booth, K., Lobello, K., Luscan, G., Hua, L., Lucas, P., Styren, S., Yang, L., Li, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0193-y · Cited by 39
Self-citationSantangelo, R., Cecchetti, G., Bernasconi, M. P., Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comı, G., & Magnani, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170186 · Cited by 46
Bullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“Anti-A β monoclonal antibodies, including bapineu-zumab (Rinne et al., 2010; Salloway et al., 2009, 2014), solanezumab (Doody et al., 2014; Farlow et al., 2012; Honig et al., 2018; Siemers et al., 2010), aducanumab (Biogen, 2019; ClinicalTrials.gov, 2019q [NCT02477800]; Sevigny et al., 2016;…”
InfluentialNanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 42
Wang, L., Liu, S., Xu, J., Watanabe, N., Mayo, K. H., Li, J., & Li, X. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15156 · Cited by 41
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.